Sevuparin is an adjunctive therapy to anti-parasite medicines to prevent the infected red blood cells from obstructing blood vessels to reduce mortality.
The grant from Vinnova will be utilized for process and method development and validation of ongoing clinical phase II project in Thailand in collaboration with the Mahidol Oxford Tropical Medicine Research Unit.
Dilaforette CEO Pirkko Sulila Tamsen said that sevuparin was selected by Vinnova in spite of high competition.
”The additional funding will take sevuparin one step further towards a treatment of severe malaria, a disease where more efficacious medications are urgently needed," Tamsen added.